PET/CT影像组学预测NSCLC患者EGFR突变状态研究的系统综述
该系统综述评估了基于PET/CT影像组学预测非小细胞肺癌(NSCLC)患者EGFR突变状态研究的方法学质量。共纳入6项研究,样本量973例(范围115-248例),采用放射组学质量评分(RQS)进行评估。结果显示RQS评分范围为13.9%至47.2%,所有研究均低于50%,主要缺陷包括分割方法、体模研究、多时间点成像、截断值分析、校准统计、前瞻性设计、临床效用及成本效益分析等方面。结论认为PET/CT影像组学特征可作为EGFR突变状态的诊断指标,但研究质量欠佳,需标准化工作流程的共识。
要点
- PET/CT影像组学特征有望预测NSCLC患者EGFR突变状态,但当前研究质量普遍较低。
- 所有纳入研究的RQS评分均低于50%,方法学存在多环节缺陷。
- 一阶统计量是最具可重复性的特征,但影像组学工作流程差异大。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the methodological quality of radiomic studies based on positron emission tomography/computed tomography (PET/CT) images predicting epidermal growth factor receptor (EGFR) mutation status in patients with non-small cell lung cancer (NSCLC).
METHODS: We systematically searched for eligible studies in the PubMed and Web of Science datasets using the terms "radiomics", "PET/CT", "NSCLC", and "EGFR". The included studies were screened by two reviewers independently. The quality of the radiomic workflow of studies was assessed using the Radiomics Quality Score (RQS). Interclass correlation coefficient (ICC) was used to determine inter rater agreement for the RQS. An overview of the methodologies used in steps of the radiomics workflow and current results are presented.
RESULTS: Six studies were included with sample sizes of 973 ranging from 115 to 248 patients. Methodologies in the radiomic workflow varied greatly. The first-order statistics were the most reproducible features. The RQS scores varied from 13.9 to 47.2%. All studies were scored below 50% due to defects on multiple segmentations, phantom study on all scanners, imaging at multiple time points, cut-off analyses, calibration statistics, prospective study, potential clinical utility, and cost-effectiveness analysis. The ICC results for majority of RQS items were excellent. The ICC for summed RQS was 0.986 [95% confidence interval (CI): 0.898-0.998].
CONCLUSIONS: The PET/CT-based radiomics signature could serve as a diagnostic indicator of EGFR mutation status in NSCLC patients. However, the current conclusions should be interpreted with care due to the suboptimal quality of the studies. Consensus for standardization of PET/CT-based radiomic workflow for EGFR mutation status in NSCLC patients is warranted to further improve research.
ADVANCES IN KNOWLEDGE: Radiomics can offer clinicians better insight into the prediction of EGFR mutation status in NSCLC patients, whereas the quality of relative studies should be improved before application to the clinical setting.
引用
- Abdurixiti M, Nijiati M, Shen R, et al. Current progress and quality of radiomic studies for predicting EGFR mutation in patients with non-small cell lung cancer using PET/CT images: a systematic review. Br J Radiol. 2021. PMID: 33882244. doi:10.1259/bjr.20201272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。